Home/PolyActiva/Wes Brazell

WB

Wes Brazell

Chief Financial Officer

Therapeutic Areas

PolyActiva Pipeline

Drug	Indication	Phase
PREZIA Glaucoma Implant	Glaucoma	Preclinical
RareSight Pediatric Retinal Pro‑drug	Rare Pediatric Retinal Diseases	Preclinical

Leadership Team at PolyActiva

Jerry St. Peter

Chief Executive Officer

Vanessa Waddell

Chief Strategy Officer

Michael Brubaker, Ph.D.

Chief Scientific Officer

View full PolyActiva profile